References

  1. TREMFYA® (guselkumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc.

  2. Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405-417.

  3. Zhuang Y, Calderon C, Marciniak SJ Jr, et al. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis. Eur J Clin Pharmacol. 2016;72(11):1303-1310.

  4. Data on file. Janssen Biotech, Inc.

  5. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007;9(6):461-467.

  6. Nestle FO, Kaplan DH, Barker J. Mechanisms of disease: psoriasis. N Engl J Med. 2009;361(5):496-509.

  7. Fujita H. The role of IL-22 and Th22 cells in human skin diseases. J Dermatol Sci. 2013;72(1):3-8.

  8. Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418-431.

  9. Griffiths CEM, Papp K, Kimball AB, et al. Two-year efficacy and safety of guselkumab for treatment of moderate to severe psoriasis: Phase 3 VOYAGE 1 trial. Presented at: European Academy of Dermatology and Venereology 26th Annual Congress; September 13-17, 2017; Geneva, Switzerland.

  10. STELARA® (ustekinumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc.

  11. Taltz® (ixekizumab) [prescribing information]. Indianapolis, IN: Eli Lilly and Company.

  12. Humira® (adalimumab) [prescribing information]. North Chicago, IL: AbbVie, Inc.

  13. SiliqTM (brodalumab) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC.

  14. Cosentyx® (secukinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceutical Corp.

  15. Enbrel® (etanercept) [prescribing information]. Thousand Oaks, CA: Immunex Corporation.